Premium
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
Author(s) -
Ruane Peter,
Strasser Simone I.,
Gane Edward J.,
Hyland Robert H.,
Shao Jiang,
DvorySobol Hadas,
Tran Tram,
Stamm Luisa M.,
Brainard Diana M.,
Nyberg Lisa,
Shafran Stephen
Publication year - 2019
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.13067
Subject(s) - regimen , medicine , sofosbuvir , hepatitis c virus , gastroenterology , virus , immunology , ribavirin
Summary This study evaluated 12‐week retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus (HCV) infection who did not achieve sustained virologic response after previous treatment with a sofosbuvir‐ and velpatasvir‐containing regimen. All 31 patients maintained a sustained virologic response 12 weeks after the last sofosbuvir/velpatasvir/voxilaprevir dose.